Transformation Into Small Cell Lung Cancer : a Mode of Resistance to Treatment
NCT03419286 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 62
Last updated 2018-02-01
Summary
The discovery of oncogenic mutations and the use of targeted therapies have transformed the management of certain tumors. Thus 12 to 15% of bronchial adenocarcinomas (AD) carry mutations of EGFR and receive from the first line inhibitors of this kinase (ITK). Despite spectacular results, relapse and resistance are quasi-general phenomena. In most known cases, EGFR-TKI resistance mechanisms involve secondary mutations of EGFR or the activation of alternative oncogenic pathways. However, in 5 to 15% of patients, resistance is manifested by the emergence of a small cell carcinoma (CPC), a cancer of neuroendocrine origin very different from AD by its cellular, molecular and epidemiological characteristics. This phenotypic transformation is an almost unique phenomenon in oncology and its molecular bases are not understood. To study this phenomenon, a Franco-Italian network was established that documented and collected cases of this rare tumor. This series is the subject of detailed anatomopathological, clinical and therapeutic documentation. This project aims to investigate the exome of one or more matched lesion regions to evaluate the evolutionary processes leading from the initial AD to the relapsing CPC. These results will guide future research on predictive markers of relapse and their targeted treatment.
Conditions
Sponsors & Collaborators
-
University Hospital, Grenoble
lead OTHER
Principal Investigators
-
Denis Moro-Sibilot, MD-PHD · University Hospital, Grenoble
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-02-29
- Primary Completion
- 2017-11-30
- Completion
- 2017-11-30
More Related Trials
-
SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013
NCT02738346 ·Status: UNKNOWN ·Phase: PHASE3
-
Topotecan for Irinotecan-Refractory SCLC
NCT00502762 ·Status: UNKNOWN ·Phase: PHASE2
-
NSCLC Relapse Therapy After Surgery and Peri-operative Chemotherapy
NCT00535275 ·Status: TERMINATED ·Phase: PHASE3
-
Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies
NCT06486428 ·Status: RECRUITING
-
Immunotherapy as Second-line in Patient With Small Cell Lung Cancer
NCT03059667 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy
NCT01159327 ·Status: TERMINATED ·Phase: PHASE2
-
Pharmacogenomic Study Realized on "Non-small Cell Lung Carcinoma"
NCT00222404 ·Status: COMPLETED
-
Retrospective Epidemiological Study of Locally Advanced Non Small Cell Lung Cancer Patients in Brazil
NCT03836469 ·Status: COMPLETED
-
The Influence of Cancer Stem-cells on Risk of Relapse in Patients Harboring Adenocarcinoma and Squamous Cell Carcinoma of the Lung
NCT04634630 ·Status: COMPLETED
-
First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.
NCT06840782 ·Status: RECRUITING ·Phase: PHASE3
-
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Small Cell Lung Cancer
NCT00002858 ·Status: UNKNOWN ·Phase: PHASE3
-
Paclitaxel in Combination With Bevacizumab in Patients With Stage IV NSCLC.
NCT04640935 ·Status: COMPLETED
-
Molecular Analysis and Treatment Options of SCLC
NCT05945745 ·Status: RECRUITING
-
Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC)
NCT00418743 ·Status: UNKNOWN
-
A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)
NCT03353675 ·Status: COMPLETED ·Phase: PHASE2
-
A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)
NCT02913443 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung Cancer
NCT00349492 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT04222972 ·Status: TERMINATED ·Phase: PHASE3
-
Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities
NCT05311709 ·Status: RECRUITING ·Phase: PHASE2
-
Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer
NCT01079481 ·Status: COMPLETED ·Phase: PHASE1
-
S0119: Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00030433 ·Status: COMPLETED ·Phase: PHASE2
-
Concurrent Once Daily Versus Twice Daily Radiotherapy for Limited Stage Small Cell Lung Cancer
NCT00433563 ·Status: COMPLETED ·Phase: NA
-
Locally Advanced NSCLC Treated With Radiochemotherapy: Phase 2 Study on the Value of a Stereotactic Boost
NCT06627738 ·Status: RECRUITING ·Phase: PHASE2
-
Randomised Study Comparing Three Chemotherapy Regimens in Non-small Cell Lung Cancer
NCT00622349 ·Status: COMPLETED ·Phase: PHASE3
-
Anlotinib in Treatment of Recurrent Small Cell Lung Cancer
NCT03732846 ·Status: UNKNOWN ·Phase: PHASE2